Greenland Mines (GRML) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neumora Therapeutics (NMRA) has outperformed Greenland Mines (GRML) over the past year, losing 74.8% versus a loss of 80.4%. Neumora Therapeutics is the larger company by market cap ($88.0 million vs $77.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRML | NMRA |
|---|---|---|
| Share price | $5.83 | $0.4683 |
| Market cap | $77.81M | $87.99M |
| 1-day change | -8.62% | -0.57% |
| YTD return | -59.65% | -73.84% |
| 1-year return | -80.37% | -74.82% |
| EPS (TTM) | $-9.74 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.00 | $3.65 |
| 52-week low | $2.82 | $0.4519 |
| Distance from 52-week high | -84.24% | -87.17% |
| Average volume | 7.99M | 1.15M |
| Shares outstanding | 13.35M | 187.90M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
GRML vs NMRA FAQ
Which is bigger, Greenland Mines or Neumora Therapeutics?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $87.99M compared with $77.81M for Greenland Mines (GRML).
Which stock has performed better over the past year, GRML or NMRA?
NMRA returned -74.82% over the past 12 months, compared with -80.37% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Greenland Mines and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.